The RNA-biomarker company announced today the appointment of Krista McKerracher as Chairperson of the Board of Directors. McKerracher is a seasoned biopharmaceutical leader with a passion for bringing new medicines to patients with life-threatening diseases. She has nearly three decades…
Sibylla Biotech and The University of Texas MD Anderson Cancer Center have announced a strategic collaboration to discover and develop novel small-molecule cancer therapies called Folding Interfering Degraders (FIDs). These therapies disrupt the proper folding of target proteins, leading to…
AstraZeneca’s supplemental New Drug Application (sNDA) for Tagrisso has been accepted and granted Priority Review in the US for treating adult patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT). If…
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a global leader in messenger RNA medicines, focused on addressing unmet medical needs in infectious diseases and rare liver and respiratory conditions, unveiled Phase 1 findings in healthy volunteers and interim Phase 1b data…
Today, Vertex Pharmaceuticals announced the presentation of new data on TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor), known in the European Union and the U.K. as KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor, at the 47th European Cystic Fibrosis Society (ECFS) Conference held June…
Today, Lilly announced that Anat Ashkenazi, the company’s Chief Financial Officer (CFO), has resigned from her position to pursue a career opportunity outside the pharmaceutical industry. David A. Ricks, the Chair and CEO of Lilly, expressed gratitude for Ashkenazi’s 23…
Today marks the launch of “Refer a Friend,” a new feature from Allē, Allergan Aesthetics’ Loyalty Rewards Program. Allē members can now invite friends and family to join, allowing both parties to save on Allergan Aesthetics products and treatments from…
Today, AbbVie announced the first patient has been treated with ABBV-383 in the CERVINO Phase 3 study. ABBV-383 is a bispecific antibody T-cell engager targeting BCMA and CD3, featuring high BCMA-avidity and low-affinity CD3 binding domains. The Phase 3, multicenter,…
UCB, a leading global biopharmaceutical company, has announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has rendered a favorable opinion, recommending the authorization for two new device presentations of bimekizumab.…
The European Commission (EC) has granted marketing authorization, maintaining orphan designation, for QALSODY® (tofersen) to treat amyotrophic lateral sclerosis (ALS) in adults associated with a mutation in the superoxide dismutase 1 gene (SOD1-ALS). QALSODY marks the first approved therapy in…
Today, Takeda announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval, under exceptional circumstances, of recombinant ADAMTS13 (rADAMTS13) for treating ADAMTS13 deficiency in both children and adult patients suffering from…
Sanofi Launches Action 2024: Global Employee Shareholder Plan Sanofi’s global employee shareholder plan, Action 2024, opens on June 4, 2024, offering approximately 80,000 employees across 56 countries the opportunity to participate. Now in its 10th year, this program underscores Sanofi’s…